{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0002","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82","upperLimit":"3405","value":"514.5"},{"groupId":"OG001","lowerLimit":"11","upperLimit":"3048","value":"150"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"Pretreatment endogenous erythropoietin level was assessed at baseline. The association between pretreatment endogenous erythropoietin level and major erythroid response was evaluated among patients who received lenalidomide alone.\n\nMajor erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \\> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.","dispersionType":"Full Range","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21 and achieve major erythroid response.","id":"OG000","title":"Arm A Patients With Major Erythroid Response"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and achieve major erythroid response.","id":"OG001","title":"Arm A Patients Without Major Erythroid Response"}],"paramType":"MEDIAN","populationDescription":"All patients randomized to arm A and all patients with 5q31.1 deletion that received lenalidomide alone","reportingStatus":"POSTED","timeFrame":"Assessed at baseline and after completion of 16 weeks of treatment","title":"Pretreatment Endogenous Erythropoietin Level","type":"SECONDARY","unitOfMeasure":"mU/mL"}